Difference between revisions of "Part:BBa K2446051:Design"
| Line 7: | Line 7: | ||
===Design Notes=== | ===Design Notes=== | ||
| − | + | Surface-expressed EGFP (surEGFP) is built by fusing CD8α signal peptid and EGFP to the transmembrane region of CD86 (NM_175862) from N terminal to C terminal. CD8α peptide guides surEGFP to be located to cell membrane. transmembrane region of CD86 supports surEGFP to fix on membrane. | |
| − | + | ||
| − | + | ||
===Source=== | ===Source=== | ||
| − | + | From IDT （gblock). | |
===References=== | ===References=== | ||
| + | [1] K. Newick, S. O'Brien, E. Moon, S. M. Albelda, CAR T Cell Therapy for Solid Tumors. Annual Review of Medicine 68, 139--152 (2017). | ||
Latest revision as of 19:59, 1 November 2017
surface-EGFP
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Design Notes
Surface-expressed EGFP (surEGFP) is built by fusing CD8α signal peptid and EGFP to the transmembrane region of CD86 (NM_175862) from N terminal to C terminal. CD8α peptide guides surEGFP to be located to cell membrane. transmembrane region of CD86 supports surEGFP to fix on membrane.
Source
From IDT （gblock).
References
[1] K. Newick, S. O'Brien, E. Moon, S. M. Albelda, CAR T Cell Therapy for Solid Tumors. Annual Review of Medicine 68, 139--152 (2017).